1. Benowitz NL. Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annu Rev Pharmacol Toxicol 2009; 49: 57-71.
2. CHAMPIX Summary of Product Characteristics. 3. Gonzales D, Rennard Sl, Nides M et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained release bupropion and placebo for smoking cessation. A randomized controlled trial. JAMA 2006; 296: 47-55. 4. West R, Baker CL, Cappelleri JC et al. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology 2008; 197: 371-377.
"By clicking "confirm" to create an account, you confirm that the information you have provided above is correct, and you agree to (i) Pfizer’s processing of your personal data, including its transfer internationally and to third parties, in accordance with the Pfizer Privacy and Cookie Policy; and (ii) Pfizer’s Website Terms of Use."